Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Myeloma Center
Explore this Website
Home
About Us
Toggle About Us menu options
Our Team
For Patients
Toggle For Patients menu options
About Multiple Myeloma, Amyloidosis, and Other Plasma Cell Disorders
Multiple Myeloma
Amyloidosis
Other Plasma Cell Disorders
Toggle Other Plasma Cell Disorders menu options
Precursor Conditions to Multiple Myeloma
Myeloma Signs and Symptoms
Amyloidosis Signs and Symptoms
Risk Factors for Multiple Myeloma and Other Plasma Cell Disorders
Diagnosing Multiple Myeloma and Other Plasma Cell Disorders
Multiple Myeloma and Plasma Cell Disorder Treatment
Understanding and Managing Side Effects
Your First Visit
Toggle Your First Visit menu options
Self-Referral
Support Groups and Helpful Links
Frequently Asked Questions
Referring Physicians
Toggle Referring Physicians menu options
Refer a Patient
Research and Clinical Trials
Toggle Research and Clinical Trials menu options
Basic and Translational Research
Bibliography
Contact Us
Weill Cornell Medicine
Care
Discover
Teach
Home
About Us
For Patients
Referring Physicians
Research and Clinical Trials
Contact Us
Home
Bibliography
Bibliography
Basic and Translational Research
Bibliography
Bibliography
Found 74 results
Author
Title
Type
[
Year
]
Filters:
First Letter Of Last Name
is
S
[Clear All Filters]
2000
Shi H
,
Djikeng A
,
Mark T
,
Wirtz E
,
Tschudi C
,
Ullu E
. 2000.
Genetic interference in Trypanosoma brucei by heritable and inducible double-stranded RNA.
.
RNA. 6(7):1069-76.
2008
Niesvizky R
,
Jayabalan DS
,
Christos PJ
,
Furst JR
,
Naib T
,
Ely S
,
Jalbrzikowski J
,
Pearse RN
,
Zafar F
,
Pekle K
et al.
. 2008.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
.
Blood. 111(3):1101-9.
Niesvizky R
,
Jayabalan DS
,
Christos PJ
,
Furst JR
,
Naib T
,
Ely S
,
Jalbrzikowski J
,
Pearse RN
,
Zafar F
,
Pekle K
et al.
. 2008.
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.
.
Blood. 111(3):1101-9.
Mark T
,
Stern J
,
Furst JR
,
Jayabalan D
,
Zafar F
,
Larow A
,
Pearse RN
,
Harpel J
,
Shore T
,
Schuster MW
et al.
. 2008.
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
.
Biol Blood Marrow Transplant. 14(7):795-8.
Mark T
,
Stern J
,
Furst JR
,
Jayabalan D
,
Zafar F
,
Larow A
,
Pearse RN
,
Harpel J
,
Shore T
,
Schuster MW
et al.
. 2008.
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
.
Biol Blood Marrow Transplant. 14(7):795-8.
Mark T
,
Stern J
,
Furst JR
,
Jayabalan D
,
Zafar F
,
Larow A
,
Pearse RN
,
Harpel J
,
Shore T
,
Schuster MW
et al.
. 2008.
Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma.
.
Biol Blood Marrow Transplant. 14(7):795-8.
2010
Gay F
,
S Rajkumar V
,
Coleman M
,
Kumar S
,
Mark T
,
Dispenzieri A
,
Pearse R
,
Gertz MA
,
Leonard J
,
Lacy MQ
et al.
. 2010.
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
.
Am J Hematol. 85(9):664-9.
2011
Niesvizky R
,
Ely S
,
Mark T
,
Aggarwal S
,
Gabrilove JL
,
Wright JJ
,
Chen-Kiang S
,
Sparano JA
. 2011.
Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma.
.
Cancer. 117(2):336-42.
2012
A Wernicke G
,
Sabbas A
,
Kulidzhanov F
,
Shamis M
,
Golster Y
,
Niesvizky R
,
Lane J
. 2012.
A single-dose conformal delivery of radiotherapy following osteoplasty : a novel approach to treatment of osteolytic metastasis in the setting of multiple myeloma.
.
HSS J. 8(2):169-74.
A Wernicke G
,
Sabbas A
,
Kulidzhanov F
,
Shamis M
,
Golster Y
,
Niesvizky R
,
Lane J
. 2012.
A single-dose conformal delivery of radiotherapy following osteoplasty : a novel approach to treatment of osteolytic metastasis in the setting of multiple myeloma.
.
HSS J. 8(2):169-74.
2013
Siegel D
,
Martin T
,
Nooka A
,
R Harvey D
,
Vij R
,
Niesvizky R
,
Badros AZ
,
Jagannath S
,
McCulloch L
,
Rajangam K
et al.
. 2013.
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
.
Haematologica. 98(11):1753-61.
Mark TM
,
Reid W
,
Niesvizky R
,
Gergis U
,
Pearse R
,
Mayer S
,
Greenberg J
,
Coleman M
,
van Besien K
,
Shore T
. 2013.
A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.
.
Biol Blood Marrow Transplant. 19(5):831-7.
Wang M
,
Martin T
,
Bensinger W
,
Alsina M
,
Siegel DS
,
Kavalerchik E
,
Huang M
,
Orlowski RZ
,
Niesvizky R
. 2013.
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.
.
Blood. 122(18):3122-8.
Kaufman JL
,
Niesvizky R
,
Stadtmauer EA
,
Chanan-Khan A
,
Siegel D
,
Horne H
,
Wegener WA
,
Goldenberg DM
. 2013.
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
.
Br J Haematol. 163(4):478-86.
Kaufman JL
,
Niesvizky R
,
Stadtmauer EA
,
Chanan-Khan A
,
Siegel D
,
Horne H
,
Wegener WA
,
Goldenberg DM
. 2013.
Phase I, multicentre, dose-escalation trial of monotherapy with milatuzumab (humanized anti-CD74 monoclonal antibody) in relapsed or refractory multiple myeloma.
.
Br J Haematol. 163(4):478-86.
2014
Geyer JT
,
Niesvizky R
,
Jayabalan DS
,
Mathew S
,
Subramaniyam S
,
Geyer AI
,
Orazi A
,
Ely SA
. 2014.
IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.
.
Mod Pathol. 27(3):375-81.
Palumbo A
,
S Rajkumar V
,
San Miguel JF
,
Larocca A
,
Niesvizky R
,
Morgan G
,
Landgren O
,
Hajek R
,
Einsele H
,
Anderson KC
et al.
. 2014.
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
.
J Clin Oncol. 32(6):587-600.
Palumbo A
,
S Rajkumar V
,
San Miguel JF
,
Larocca A
,
Niesvizky R
,
Morgan G
,
Landgren O
,
Hajek R
,
Einsele H
,
Anderson KC
et al.
. 2014.
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
.
J Clin Oncol. 32(6):587-600.
Palumbo A
,
S Rajkumar V
,
San Miguel JF
,
Larocca A
,
Niesvizky R
,
Morgan G
,
Landgren O
,
Hajek R
,
Einsele H
,
Anderson KC
et al.
. 2014.
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
.
J Clin Oncol. 32(6):587-600.
Palumbo A
,
S Rajkumar V
,
San Miguel JF
,
Larocca A
,
Niesvizky R
,
Morgan G
,
Landgren O
,
Hajek R
,
Einsele H
,
Anderson KC
et al.
. 2014.
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
.
J Clin Oncol. 32(6):587-600.
Palumbo A
,
S Rajkumar V
,
San Miguel JF
,
Larocca A
,
Niesvizky R
,
Morgan G
,
Landgren O
,
Hajek R
,
Einsele H
,
Anderson KC
et al.
. 2014.
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
.
J Clin Oncol. 32(6):587-600.
Kumar SK
,
Bensinger WI
,
Zimmerman TM
,
Reeder CB
,
Berenson JR
,
Berg D
,
Hui A-M
,
Gupta N
,
Di Bacco A
,
Yu J
et al.
. 2014.
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
.
Blood. 124(7):1047-55.
Kumar SK
,
Berdeja JG
,
Niesvizky R
,
Lonial S
,
Laubach JP
,
Hamadani M
,
A Stewart K
,
Hari P
,
Roy V
,
Vescio R
et al.
. 2014.
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
.
Lancet Oncol. 15(13):1503-12.
Mark TM
,
Bowman IA
,
Rossi AC
,
Shah M
,
Rodriguez M
,
Quinn R
,
Pearse RN
,
Zafar F
,
Pekle K
,
Jayabalan D
et al.
. 2014.
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma.
.
Leuk Lymphoma. 55(12):2842-9.
2015
A Stewart K
,
S Rajkumar V
,
Dimopoulos MA
,
Masszi T
,
Spicka I
,
Oriol A
,
Hajek R
,
Rosiñol L
,
Siegel DS
,
Mihaylov GG
et al.
. 2015.
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
.
N Engl J Med. 372(2):142-52.
1
(current)
2
3
next ›
last »